Hansa Medical AB (HMED):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Hansa Medical AB (HMED) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10161
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:52
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スウェーデン
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Hansa Medical AB (Hansa Medical) is a biopharmaceutical company that focuses on the development of novel immunomodulatory enzymes for transplantation and acute autoimmune diseases. The company’s lead project, IdeS is a proprietary antibody-degrading enzyme in late stage clinical development for kidney transplant patients. IdeS has potential for further development in other solid organ transplants and a range of acute autoimmune indications. Its preclinical assets include NiceR for recurring treatment in autoimmune disease, transplantation and cancer; and EnzE, a cancer immunotherapy. Hansa Medical out-licensed its HBP-assay (serum quantification of Heparin-Binding Protein), a novel diagnostic method to help predict severe sepsis in patients with infectious disease symptoms to Axis-Shield Diagnostics. Hansa Medical is headquartered in Lund, Sweden.

Hansa Medical AB (HMED) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Hansa Medical AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Hansa Medical AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Hansa Medical AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Hansa Medical AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Hansa Medical AB, Medical Devices Deals, 2012 to YTD 2018 10
Hansa Medical AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Hansa Medical AB, Pharmaceuticals & Healthcare, Deal Details 12
Equity Offering 12
Hansa Medical to Raise USD65.5 Million in Private Placement of Shares 12
Hansa Medical Plans to Raise USD21 Million in Private Placement of Shares 13
Hansa Medical Raises USD29.3 Million in Rights Offering 15
Hansa Medical Raises Funds through Private Placement of Shares 16
Hansa Medical Completes Rights Offering Of Shares For US$5.7 Million 17
Hansa Medical Completes Private Placement Of Shares For US$4 Million 18
Acquisition 19
Hansa Medical Acquires Immago Biosystems 19
Hansa Medical AB – Key Competitors 20
Hansa Medical AB – Key Employees 21
Hansa Medical AB – Locations And Subsidiaries 22
Head Office 22
Other Locations & Subsidiaries 22
Recent Developments 23
Financial Announcements 23
Nov 01, 2018: Hansa Medical interim report July – September 2018 23
Jul 19, 2018: Hansa Medical interim report April – June 2018 25
Apr 25, 2018: Hansa Medical Reports January–March 2018 Results 27
Feb 14, 2018: Hansa Medical Year-End Report 2017 29
Nov 14, 2017: Hansa Medical Interim report July – September 2017 32
Jul 20, 2017: Hansa Medical Interim report April-June 2017 33
Apr 26, 2017: Hansa Medical: Interim report January – March 2017 35
Feb 15, 2017: Hansa Medical Year-End Report 2016 37
Corporate Communications 40
Mar 20, 2018: Hansa Medical Appoints Soren Tulstrup As President And CEO 40
Mar 31, 2017: Hansa Medical appoints Sam Agus as new Chief Medical Officer 41
Legal and Regulatory 42
May 19, 2017: IdeS selected for EMA Priority Medicines (PRIME) scheme 42
Product News 43
03/29/2017: Top-line clinical results from US study with lead candidate IdeS to be presented at the American Transplant Congress 43
02/14/2018: Intermediate evaluation of a sub-population in the Highdes study demonstrates good kidney function 5.5 months (median) post transplantation 44
Product Approvals 45
May 19, 2017: IdeS selected for EMA Priority Medicines (PRIME) scheme 45
Clinical Trials 46
Jan 04, 2018: Completed enrollment in Hansa Medical’s international multi-center Phase II study Highdes 46
Jan 03, 2018: Finalized Enrollment in US Phase II study with IdeS in Highly Sensitized Patients 47
Aug 02, 2017: The New England Journal of Medicine publishes results from Phase II studies of Hansa Medical’s lead candidate IdeS in highly sensitized patients 49
Jun 20, 2017: First patient treated in Phase II study with IdeS in anti-GBM antibody disease 50
Feb 16, 2017: Novel pre-clinical in vivo data demonstrate the treatment potential of IdeS in Guillain-Barre syndrome 51
Appendix 52
Methodology 52
About GlobalData 52
Contact Us 52
Disclaimer 52

List of Tables
Hansa Medical AB, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Hansa Medical AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Hansa Medical AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Hansa Medical AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Hansa Medical AB, Deals By Therapy Area, 2012 to YTD 2018 9
Hansa Medical AB, Medical Devices Deals, 2012 to YTD 2018 10
Hansa Medical AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Hansa Medical to Raise USD65.5 Million in Private Placement of Shares 12
Hansa Medical Plans to Raise USD21 Million in Private Placement of Shares 13
Hansa Medical Raises USD29.3 Million in Rights Offering 15
Hansa Medical Raises Funds through Private Placement of Shares 16
Hansa Medical Completes Rights Offering Of Shares For US$5.7 Million 17
Hansa Medical Completes Private Placement Of Shares For US$4 Million 18
Hansa Medical Acquires Immago Biosystems 19
Hansa Medical AB, Key Competitors 20
Hansa Medical AB, Key Employees 21
Hansa Medical AB, Subsidiaries 22

List of Figures
Hansa Medical AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Hansa Medical AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Hansa Medical AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Hansa Medical AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Hansa Medical AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Hansa Medical AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Hansa Medical AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Hansa Medical AB, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Hansa Medical AB (HMED):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Parenteral Drug India Ltd (PDPL):企業の財務・戦略的SWOT分析
    Summary Parenteral Drug India Ltd (PDIL) is a healthcare company that manufactures pharmaceutical products. The company provides products such as solid and liquid orals, IV fluids, oncology products and anaesthesia products. It offers IV fluids such as carbohyrated and electrolytes; diuretics, dialy …
  • LKQ Corporation:企業のM&A・事業提携・投資動向
    LKQ Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's LKQ Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestm …
  • Intermountain Rural Electric Association:企業の戦略的SWOT分析
    Intermountain Rural Electric Association - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and …
  • Inretail Peru Corp. (INRETC1):企業の財務・戦略的SWOT分析
    Inretail Peru Corp. (INRETC1) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Cutispharma Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary CutisPharma Inc (CutisPharma) is a pharmaceutical company that develops and distributes kits. The company offers products such as oral suspensions, suppositories, oral solutions, and topical, among others. Its oral solutions and oral suspensions include mouthwashes, anti-microbial, and PPIs; …
  • Celanese Corp (CE):企業の財務・戦略的SWOT分析
    Celanese Corp (CE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Izumi Co., Ltd.:戦略・SWOT・企業財務分析
    Izumi Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Izumi Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Kansas City Power & Light Co:電力:M&Aディール及び事業提携情報
    Summary Kansas City Power & Light Co. (KCP&L), a subsidiary of Great Plains Energy, Inc., is an integrated energy utility that generates, transmits, distributes, and sells electricity. The company generates electricity from nuclear, solar, biogas, wind, hydro, coal, and natural gas sources. Through …
  • New Age Metals Inc:企業の戦略・SWOT・財務情報
    New Age Metals Inc - Strategy, SWOT and Corporate Finance Report Summary New Age Metals Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Gas y Petroleo del Neuquen SA:石油・ガス:M&Aディール及び事業提携情報
    Summary Gas y Petroleo del Neuquen SA (Gas Y Petroleo) operates as an oil and gas exploration company. It is engaged in the production and supply of hydrocarbon resources. The company holds 36 contracts with other companies, to develop exploratory and hydrocarbon exploitation activities. It is also …
  • Mitobridge Inc-製薬・医療分野:企業M&A・提携分析
    Summary Mitobridge Inc (Mitobridge), formerly Mitokyne, Inc. is a drug development company that discovers and develops small molecule therapeutics. The company offers products that enhance the mitochondrial functions. It develops therapies for rare diseases and then expand into more common diseases. …
  • Apache Corp (APA):企業の財務・戦略的SWOT分析
    Apache Corp (APA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Instituto Costarricense de Electricidad:企業の戦略的SWOT分析
    Instituto Costarricense de Electricidad - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and m …
  • NuStar Energy LP (NS):企業の財務・戦略的SWOT分析
    NuStar Energy LP (NS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Mizuno Corporation (8022):企業の財務・戦略的SWOT分析
    Mizuno Corporation (8022) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Omron Corp (6645):企業の財務・戦略的SWOT分析
    Omron Corp (6645) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Vp Plc (VP.):企業の財務・戦略的SWOT分析
    Summary Vp Plc (Vp) is a provider of equipment rental services. The company offers material handling equipment rental for housing, general construction and other industries; equipment for shoring and piling, pipe stoppers, pumps, temporary bridges and excavation support equipment for water, gas, civ …
  • Clinical Innovations LLC:医療機器:M&Aディール及び事業提携情報
    Summary Clinical Innovations LLC (Clinical Innovations), a portfolio company of EQT AB, is a medical device company that researches and manufactures healthcare products to improve the lives of mothers and their babies. The company focuses on labor, delivery and neonatal intensive care. Its major pro …
  • Trinity Health:企業の戦略・SWOT・財務分析
    Trinity Health - Strategy, SWOT and Corporate Finance Report Summary Trinity Health - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • C-Rad AB (CRAD B)-医療機器分野:企業M&A・提携分析
    Summary C-Rad AB (C-Rad) is a medical device company that develops, manufactures and markets advanced radiation therapy equipments. The company offers products and solutions for patient positioning, tumor localization, and radiation treatment systems. Its products include sentinel 4DCT, catalyst HD, …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆